Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (131-140 of 181) with videos related to

Pageof 19
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 9, 2026
Natural history of anal HSIL and predictive value of cytology and HPV biomarkers in MSM living with HIV: a prospective cohort studyAna C Silva-Klug, Sònia Paytubi, Loris Trenti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 7, 2013
[Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders], Daniel Podzamczer Palter, José A Muñoz-Moreno, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 13, 2025
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trialJose M Miro, Ferran Torres, Christian Manzardo, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsJuan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2020
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)Arkaitz Imaz, Juan M Tiraboschi, Jordi Niubó, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2008
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)Angeles Jaén, Anna Esteve, Josep M Miró, et al.
Medicina Clinica|April 26, 2005
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]Angeles Jaén, Jordi Casabona, Anna Esteve, et al.
Pageof 19

Showing results (131-140 of 181) with videos related to

Sort By:
Pageof 19
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 9, 2026
Natural history of anal HSIL and predictive value of cytology and HPV biomarkers in MSM living with HIV: a prospective cohort studyAna C Silva-Klug, Sònia Paytubi, Loris Trenti, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 1, 2010
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyFrank A Post, Graeme J Moyle, Hans Jürgen Stellbrink, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 7, 2013
[Consensus statement on the clinical management of human immunodeficiency virus-associated neurocognitive disorders], Daniel Podzamczer Palter, José A Muñoz-Moreno, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 13, 2025
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trialJose M Miro, Ferran Torres, Christian Manzardo, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|September 1, 2015
Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsJuan Berenguer, Antonio Rivero, Antonio Javier Blasco, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2020
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)Arkaitz Imaz, Juan M Tiraboschi, Jordi Niubó, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2008
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)Angeles Jaén, Anna Esteve, Josep M Miró, et al.
Medicina Clinica|April 26, 2005
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]Angeles Jaén, Jordi Casabona, Anna Esteve, et al.
Pageof 19